TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in...
LEXINGTON, Mass., Jan. 8, 2020 /PRNewswire/ — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first patient with AGEN1223. AGEN1223 is a novel...
Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA Milan, Italy and Morristown, NJ, USA, January 9, 2020 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA:...
Vault Payments enables sponsors and CROs to automatically create, track, and report payments in Vault CTMS for greater accuracy and visibility BARCELONA, Spain–(BUSINESS WIRE)–Veeva Systems (NYSE:VEEV) today introduced Veeva Vault Payments, a new add-on...
Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP) Regeneron plans to discuss regulatory submission with regulatory...
Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks Interim data support candidates’ potential to become foundational NASH therapies Top-line data from full...
Email
Text